Skip to content

Author

Jinjin Liang

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

Efficacy and safety of obinutuzumab β in patients with active systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

BACKGROUND B cells play a central role in the pathogenesis of systemic lupus erythematosus (SLE) and are a therapeutic target. We therefore assessed the efficacy and safety of obinutuzumab β, a glycoengineered type II anti-CD20 monoclonal antibody, in patients with active SLE. METHODS In this multicentre, randomised,...

Yu-Hui Li, Gui-Xiu Shi, Guo-Ping Jiang et al. · 0 citations
Open access Aug 2026

Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial.

Although CD20-directed B cell depletion has long been used in neuromyelitis optica spectrum disorder (NMOSD), high-quality, large-scale, randomized controlled trials remain limited. In this multicenter, randomized, double-blind phase 3 trial, we evaluated obinutuzumab β (MIL62), a novel glycoengineered type II anti-CD2...

Lei Wu, Liangliang Gu, Wei-Hao Fan et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.